Marshall Wace North America’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Marshall Wace North America’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-88,267	Closed	-$452K	–	1700
2019 Q4	$452K	Sell	88,267 -476	-0.5%	-$2.64K	﹤0.01%	843
2019 Q3	$573K	Buy	+88,743	New	+$612K	﹤0.01%	793
2019 Q2	–	Sell	-1,466	Closed	-$16K	–	1749
2019 Q1	$16K	Hold	1,466	–	–	﹤0.01%	1413
2018 Q4	$12K	Sell	1,466 -1,322	-47%	-$19.1K	﹤0.01%	1413
2018 Q3	$54K	Sell	2,788 -55,294	-95%	-$1.01M	﹤0.01%	880
2018 Q2	$1.05M	Buy	+58,082	New	+$857K	0.01%	917
2018 Q1	–	Sell	-2,438	Closed	-$103K	–	1776
2017 Q4	$103K	Hold	2,438	–	–	﹤0.01%	1312
2017 Q3	$137K	Buy	+2,438	New	+$411K	﹤0.01%	1193

Other funds holding SIOX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace North America's SIOX Position: Q1 2020 in Review

Marshall Wace North America sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 88,267 shares — an estimated $452K sold.

Marshall Wace North America first reported a position in SIOX in Q3 2017 and held it in 8 quarters. The position peaked at $1.05M in Q2 2018. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

Marshall Wace North America reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Marshall Wace North America sold 88,267 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $452K.
Marshall Wace North America first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 8 quarters.
Marshall Wace North America's Sio Gene Therapies Inc. Common Stock position peaked at $1.05M in Q2 2018.
42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.